Navigation Links
Montméd obtains reimbursement of Timesulin, the smart insulin pen timer cap, by major insurance companies in Canada
Date:8/26/2014

MONTREAL, Aug. 26, 2014  When it comes to diabetes supplies, innovations are often accused of having very little clinical relevance. But Timesulin happens to answer a real medical need.

Fitting most of insulin disposable pen on the market, Timesulin shows how long it's been since your last injection. One advantage being, indeed, preventing from missed or double insulin doses. Very easy to use, Timesulin starts automatically once it is put back on the insulin pen after an injection. There is no settings or complicated handling needed. Therefore, it enhances safety and eases daily worries for diabetic patients.

According the 2010 Novo Nordisk Gapp study (conducted among almost 3,000 physicians and patients in 8 countries), more than four in 10 people with diabetes say they struggle to effectively control their blood sugar either it is because they forget a dose, fail to take their insulin treatment properly or double their dose.  Also, 67% of patients taking insulin are concerned about experiencing a hypoglycemic event in the future.

From a public health perspective, the disease and its treatments can lead to a variety of short-term and long-term complications such as infections, slow wound healing, cardiovascular disease, vision loss, kidney failure, nerve damage, problems with pregnancy, oral disease and so on. Those health issues, as well as diabetes management itself, result in reduced quality of life, work limitations and higher risk of early death. They also greatly increase the need for health care resources and the economic burden of diabetes for society.

Widely used, Timesulin cap could help avoid hypo or hyperglycemic episodes and related complications and reduce future diabetes-related expenditures.

By securing reimbursement for Timesulin, Montméd and insurance companies have shown their understanding of the complexity of care in diabetes and their commitment to diversify the ways to make diabetes management simplermake diabetes management simplermake diabetes management simpler.

"For Montméd, having Timesulin reimbursed by benefit plans was a matter of equality. Since public healthcare coverage in Canada is rather uneven across the country because it is within competences of provinces and territories, we wanted to ensure accessibility to Timesulin for as many diabetics as possible because it can really make a difference in their lives." Gino Henry, General Manager of Montméd for Canada.

Timesulin's reimbursement has been approved by:

Great West Life

Manulife Financiel

Sun Life Financial

Industrial Alliances

Medavie Blue Cross

Empire Life

Standard Life

Equitable Life

Desjardins

About montméd :

Montméd is a Canadian manufacturer and distributor of medical devices within the area of diabetes and self-care. Its range of products includes insulin syringes, pen needles, thermometers, blood pressure monitors, skin care, insulin cooling wallet and so on. Montméd focuses on bringing a unique touch to each of its product, aligned with users' needs. It offers advices, news and educational tools to both patients and health-care professionals through its Health Street program. 
The company also provides global distribution and marketing services for other medical equipment firms.

"Simple and unique innovations that make a difference"

Version française disponible sur demande.


'/>"/>
SOURCE Montméd
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. montméd, Inc. to Market FRiO Insulin Wallets in 20 countries of Middle East and North Africa
2. Montmed to Participate in 2013 Advanced Technologies and Treatments for Diabetes Conference
3. montmed to participate in Vascular 2013
4. Montmed to Launch DiaClin General & Diabetic Skin Care Product Line for Canadian Marketplace
5. Biodel Obtains Exclusive License to Aegis Therapeutics Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations
6. 3SBio Obtains SFDA Approval to Join Global Phase III Trial for Voclosporin
7. Rheumatoid Arthritis New Major Clinical Target After Mesoblast Obtains Positive Results in Inflammatory Arthritis
8. AbGenomics International Obtains FDA Agreement on Its Phase 2 Clinical Trial Plans
9. Andrew Technologies Obtains Patent for Visceral Lipectomy Application from USPTO
10. BioElectronics Obtains Additional US Patent For Its Unique Pain Devices
11. Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will ... and webcast on Friday, November 3, 2017, beginning at ... at approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... financial performance and guidance for 2018, Hill-Rom executives will ... operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor ... on sciatica in a new episode of "Success Files," which is an award-winning ... innovation and investigates each subject in-depth with passion and integrity. , Sciatica occurs ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
(Date:10/12/2017)... , ... October 12, 2017 , ... On Saturday, October ... treadmill relay – Miles by Moonlight to raise money for the American Heart Association ... more. , Teams will work together to keep their treadmills moving for 5 ...
Breaking Medicine News(10 mins):